Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
R129674-10mg | 10mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $53.90 | |
R129674-50mg | 50mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $75.90 | |
R129674-250mg | 250mg | In stock | $342.90 | |
R129674-1g | 1g | In stock | $1,231.90 |
Selective PDE4 inhibitor
Synonyms | rolipram|61413-54-5|(R,S)-rolipram|ZK 62711|Rolipramum [Latin]|(+/-)-Rolipram|4-(3-(cyclopentyloxy)-4-methoxyphenyl)pyrrolidin-2-one|4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone|Rolipramum|4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidin-2-one|A |
---|---|
Specifications & Purity | Moligand™, ≥97% |
Biochemical and Physiological Mechanisms | Rolipram is a selective, cell-permeable inhibitor of cAMP-specific PDE (phosphodiesterase) (PDE4, IC50=1 μM). This compound has been shown to inhibit PDE4 activity in human cavernosal tissue, which interrupts the signal transduction pathway of erectile re |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of phosphodiesterase 4A;Inhibitor of phosphodiesterase 4B;Inhibitor of phosphodiesterase 4C;Inhibitor of phosphodiesterase 4D |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Rolipram enhances tissue protection, anatomical repair and functional recovery. It is used to treat asthma, arthritis, Huntington′s disease and multiple sclerosis. Rolipram inhibits injury-induced reductions in cyclic AMP, which is associated with acute central nervous system injury. It functions as an antidepressant, stimulates neurite outgrowth and axonal regeneration in the presence of myelin inhibitors. |
ALogP | 2.2 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one |
---|---|
INCHI | InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18) |
InChi Key | HJORMJIFDVBMOB-UHFFFAOYSA-N |
Canonical SMILES | COC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3 |
Isomeric SMILES | COC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3 |
WGK Germany | 3 |
RTECS | UY5749237 |
Alternate CAS | 61413-54-5 |
PubChem CID | 5092 |
NSC Number | 760125 |
MeSH Entry Terms | Rolipram;ZK 62711;ZK-62711;ZK62711 |
Molecular Weight | 275.34 |
CAS Registry No. | 61413-54-5 |
---|---|
DrugBank Ligand | DB04149, DB03606 |
Wikipedia | Rolipram |
ChEBI | CHEBI:104872 |
PubChem CID | 5092 |
ChEMBL Ligand | CHEMBL63 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
K1814186 | Certificate of Analysis | Apr 07, 2024 | R129674 |
F1502084 | Certificate of Analysis | Jan 25, 2023 | R129674 |
A2305711 | Certificate of Analysis | Nov 16, 2022 | R129674 |
A2305712 | Certificate of Analysis | Nov 16, 2022 | R129674 |
A2305734 | Certificate of Analysis | Nov 16, 2022 | R129674 |
A2305735 | Certificate of Analysis | Nov 16, 2022 | R129674 |
K1814185 | Certificate of Analysis | Jul 18, 2022 | R129674 |
Solubility | Soluble in water (0.2 mg/mL ), DMSO (7.3 mg/ml ), ethanol (7 mg/ml warm), DMF (~10 mg/ml ), DMF:PBS (pH 7.2, 1:9) (~0.5 mg/ml ), and acetone (25 mg/ml). |
---|---|
Sensitivity | heat sensitive |
Melt Point(°C) | 130-134°C |
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H335:May cause respiratory irritation H302:Harmful if swallowed |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P271:Use only outdoors or in a well-ventilated area. P270:Do not eat, drink or smoke when using this product. P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing. P403+P233:Store in a well-ventilated place. Keep container tightly closed. P362+P364:Take off contaminated clothing and wash it before reuse. P330:Rinse mouth. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P301+P317:IF SWALLOWED: Get medical help. P337+P317:If eye irritation persists: Get medical help. P332+P317:If skin irritation occurs: Get medical help. P319:Get medical help if you feel unwell. |
WGK Germany | 3 |
RTECS | UY5749237 |
Merck Index | 8251 |
Starting at $173.90
1. Huang Z, Mancini JA. (2006) Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.. Curr Med Chem, 13 (27): (3253-62). [PMID:17168849] |
2. Normann C, Berger M. (2008) Neuroenhancement: status quo and perspectives.. Eur Arch Psychiatry Clin Neurosci, 258 Suppl 5 (3): (110-4). [PMID:18985306] |
3. García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R. (2012) Phosphodiesterases as therapeutic targets for Alzheimer's disease.. ACS Chem Neurosci, 3 (11): (832-44). [PMID:23173065] |
4. Kumar N, Goldminz AM, Kim N, Gottlieb AB. (2013) Phosphodiesterase 4-targeted treatments for autoimmune diseases.. BMC Med, 11 (3): (96). [PMID:23557064] |
5. Ahmad F et al.. (2021) Chemical Stimulation of Rodent and Human Cortical Synaptosomes: Implications in Neurodegeneration.. Cells, 10 (5): [PMID:34065927] |
6. Severino J et al.. (2022) Controlled X-chromosome dynamics defines meiotic potential of female mouse in vitro germ cells.. EMBO J, 41 (12): (e109457). [PMID:35603814] |
7. Shelly M et al.. (2010) Local and long-range reciprocal regulation of cAMP and cGMP in axon/dendrite formation.. Science, 327 (5965): (547-52). [PMID:20110498] |
8. Murase Y et al.. (2020) Long-term expansion with germline potential of human primordial germ cell-like cells in\xa0vitro.. EMBO J, 39 (21): (e104929). [PMID:32954504] |
9. Nelissen E et al.. (2021) Soluble Guanylate Cyclase Stimulator Vericiguat Enhances Long-Term Memory in Rats without Altering Cerebral Blood Volume.. Biomedicines, 9 (8): [PMID:34440254] |
10. Nelissen E et al.. (2022) The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms.. Sci Rep, 12 (3589). [PMID:35246566] |